Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agenus Inc. - Common Stock (NQ:AGEN)

3.115 -0.125 (-3.86%)
Streaming Delayed Price Updated: 10:22 AM EST, Jan 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Agenus Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Thursday's session: top gainers and losers ↗
Via Chartmill
Which stocks are moving on Thursday? ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Agenus (AGEN) Q3 2024 Earnings Call Transcript ↗
Agenus (AGEN) Q3 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
Examining the Future: Agenus's Earnings Outlook ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 12, 2025 ↗
 
Via Benzinga
News headline image
Agenus's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Agenus (AGEN) Q1 2025 Earnings Call Transcript ↗
Agenus (AGEN) Q1 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Agenus (AGEN) Q4 2024 Earnings Call Transcript ↗
Agenus (AGEN) Q4 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
AGENUS INC (NASDAQ:AGEN) Reports Mixed Q3 2025 Earnings, Driven by One-Time Gain ↗
Agenus reports mixed Q3 2025 results with a revenue miss but strong clinical progress for its cancer drug BOT/BAL, including a new Phase 3 trial. 
Via Chartmill
News headline image
Insights Ahead: Agenus's Quarterly Earnings ↗
 
Via Benzinga
News headline image
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025.... 
Via MarketMinute
Topics Intellectual Property
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Monday's pre-market session: top gainers and losers ↗
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Agenus Posts 48% Q2 Revenue Miss ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang ↗
Zydus acquires two Agenus biologics facilities in California for $75 million, expanding U.S. CDMO presence and securing rights to key cancer drug manufacturing. 
Via Benzinga
News headline image
Insights Ahead: Agenus's Quarterly Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 11, 2025 ↗
 
Via Benzinga
News headline image
Agenus Stock Is Trading Higher Tuesday: What's Going On? ↗
Agenus announced it signed a partnership agreement with Zydus Lifesciences to expand patient access to Botensilimab and Balstilimab. 
Via Benzinga
News headline image
Tuesday's pre-market session: top gainers and losers ↗
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Credo Technology Group Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Here are the top movers in Tuesday's session. ↗
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
Agenus (AGEN) Q4 2024 Earnings Call Transcript ↗
AGEN earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development ↗
Agenus secures a $22M mortgage and announces a strategic realignment to focus on botensilimab/balstilimab in MSS colorectal cancer. 
Via Benzinga
News headline image
Earnings Scheduled For March 11, 2025 ↗
 
Via Benzinga
News headline image
Agenus (AGEN) Q3 2024 Earnings Call Transcript ↗
AGEN earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.